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Abstract
Background—Mycophenolic acid (MPA) is used off-label to treat many forms of
glomerulonephritis.
Objective—To evaluate the pharmacokinetics of MPA and its glucuronide (MPAG) in
antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis patients with renal
manifestations and to determine the effects of clinical (urinary protein excretion, serum albumin,
creatinine clearance) and demographic (age, race, sex) variables on MPA and MPAG
pharmacokinetics.
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Methods—Twenty-three patients taking MPA at steady-state were evaluated. Plasma and urine
samples were collected over 24 hours. Analyses included noncompartmental pharmacokinetics and
statistics including Mann-Whitney U test and univariate/multiple regression.
Results—MPA clearance (Cl/F 288 ± 154 mL/min) was approximately 2-fold higher than
previously reported from transplant patients and predicted by weight and race (ranked MPA Cl/F =
−11.766 + 0.2035 [wt] + 4.9578 [race]; R2 41.8%; p = 0.005). Creatinine clearance (CrCl) less than
60 mL/min resulted in higher MPA exposure, total area under the curve (AUC)0-12, and AUC6-12,
as well as unbound AUC0-12. The metabolic ratio (MPAGAUC/MPAAUC) of 8.67 ± 5.57 was lower
than that previously reported in renal transplant recipients.
Conclusions—Diminished kidney function (eg, CrCl <60 mL/min) demonstrated enhanced MPA
and MPAG exposure in patients with ANCA vasculitis. However, unlike renal transplant recipients,
patients with ANCA vasculitis had enhanced Cl/F and diminished metabolic ratio, suggesting the
need to comprehensively evaluate the role of disease-specific factors on MPA pharmacokinetics.
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antineutrophil cytoplasmic antibody–associated vasculitis; individualized therapy; mycophenolic
acid; pharmacokinetics
Mycophenolic acid (MPA) is used off-label for treatment of immune-mediated disorders and
is approved by the Food and Drug Administration (FDA) for prevention of transplant rejection.
1-6 Three studies evaluated the efficacy of MPA in small-vessel vasculitis.7-9 In one of these,
we reported 3-fold improvements in disease activity (Birmingham Vasculitis Activity Score)
in patients experiencing disease relapse compared with those defined as treatment resistant.
While patients with kidney manifestations of vasculitis are similar to renal transplant recipients
in that they can have alterations in glomerular filtration rate, they also often have altered serum
albumin, urinary protein, and markers of inflammation.
Since interindividual variability in MPA pharmacokinetics has been documented in transplant
recipients, therapeutic plasma monitoring has been suggested to improve immunosuppressive
outcomes.10-13 Area under the plasma concentration–time curve from 0 to 12 hours
(AUC0-12) of 30–60 mg•h/L and trough plasma concentrations of 1–3.5 mg/L were suggested
as targets for triple combination immunosuppressive therapy in kidney and heart transplant
patients.13,14 Target ranges for MPA in autoimmune kidney diseases, such as lupus nephritis
and antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis, have not been
established.
The primary purpose of this study was to evaluate the pharmacokinetics of total and unbound
MPA and its metabolite, phenolic O-glucuronide (MPAG), in ANCA vasculitis. The secondary
objectives were to determine the effects of clinical parameters (urinary protein to creatinine
excretion ratio [UP:Cr], serum albumin, creatinine clearance [CrCl]) and demographic
variables (age, race, sex) on pharmacokinetics of the drug and its metabolite.
Methods
Patients
Patients with biopsy-confirmed ANCA vasculitis receiving MPA therapy (as mycophenolate
mofetil) and at steady-state were eligible. Concomitant therapies with other
immunosuppressants were permitted and recorded. Patients entered the institution's general
clinical research unit for 24 hours for assessment of the pharmacokinetics of MPA at the dose
and interval that was prescribed. Patients were fasting at study initiation and were then fed a
standard diet. CrCl (calculated by the Cockcroft-Gault equation15), UP:Cr, serum albumin, and
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serum creatinine were obtained/recorded. The study was approved by the university's
Institutional Review Board in accordance with the Declaration of Helsinki.
Pharmacokinetic Study
After baseline blood samples were obtained for measurement of a trough plasma concentration
(Ctr), patients were instructed to take their morning dose of MPA. Plasma samples (7.5 mL)
were obtained at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours, immediately centrifuged for 10
minutes at 4 °C, aliquoted, transferred to plastic screw-top tubes, and stored at −80 °C until
assay. Urine was collected at intervals of 0–6, 6–12, and 12–24 hours into acidified (15 mL 6
N HCl) collection containers; volumes were recorded and 2-mL aliquots were stored at −80 °
C until assay. Plasma and urine samples were processed and assayed as described previously.
16,17 Unbound plasma fraction was determined as previously described.17 Plasma and urine
standard curves for MPA were linear over the ranges of 0.2–200 and 1–50 mg/L, respectively.
Plasma and urine standard curves for MPAG were linear over the ranges of 1–200 and 5–1500
mg/L, respectively. MPAG concentrations were represented in terms of MPA equivalents by
multiplying the MPAG concentration by 0.646 (molecular mass of MPA to MPAG) and are
reported in milligrams per liter. The amount of MPA available from a dose of mycophenolate
mofetil was estimated as 72% of the dose.
Pharmacokinetic Analysis
Noncompartmental pharmacokinetic analysis of total and unbound MPA and total MPAG was
conducted using WinNonlin v4.1 (Pharsight, Mountain View, CA). Maximum concentration
(Cmax), time to Cmax (tmax), Ctr at 12 hours, AUC0-12, oral clearance (Cl/F), renal clearance
(Clr), and mean residence time (MRT) were recorded. Both concentration and AUC parameters
were dose-normalized, and the clearance data were adjusted to a 70-kg patient based on a
scaling method, using a power of 0.75.18 We made the assumption that bioavailability (F) was
equal to 1, as reported previously.11 AUC12-24 and AUC6-12 were calculated, and the latter
was used to estimate apparent enterohepatic recycling.19,20 Amount of MPA and MPAG in
urine over each collection was determined by multiplying concentration by volume. MPA and
MPAG amounts in urine (Ae) were computed for 0–12 hours by adding the Ae for the first 2
intervals. Clr for the 0- to 12-hour time was calculated by Ae0-12/AUC0-12.
Statistics
Descriptive analyses for pharmacokinetic and demographic variables and laboratories included
means, standard deviations, and medians, as appropriate. Bivariate assessments of the key
characteristics (serum albumin, UP:Cr, CrCl, age, weight, race, prednisone dose) versus each
pharmacokinetic parameter of interest (MPA Cl/F, AUC0-12, AUC6-12, Ctr12, Clr, Clunb, and
AUCunb 0-12; as well as MPAG AUC0-12 and Clr) were assessed by Spearman rank correlations.
The effect of cyclosporine on MPA could not be directly assessed, because only 3 patients
were receiving the drug. The correlations and resultant p values from the bivariate assessments
were analyzed for possible inclusion into multiple regression models that predicted
pharmacokinetic parameters. Correlations with a p value less than 0.15 were selected for
incorporation into the multiple regression models. Variables were transformed to ensure that
each followed a normal distribution. Model building for analysis of determinants of the
parameters identified above consisted of multiple linear regression analysis with forward
addition of variables as well as backward elimination, noting influences on the coefficients of
the primary predictors. The final model was selected based on significance of each variable on
predicting the parameters in the model, as well as the overall R2 of the model.
Comparison between clinical groups based on CrCl (<60 vs ≥60 mL/min) and UP:Cr (<500
vs ≥500) was analyzed by nonparametric Mann-Whitney U test. It was not possible to compare
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serum albumin groups, as there were no significant deviations from the laboratory's reference
range.
Results
Twenty-three patients with biopsy-confirmed ANCA small-vessel vasculitis completed the
MPA/MPAG pharmacokinetics study. Patient demographics included age 53 ± 14 years, 57%
female, 78% white, and weight 87 ± 19 kg. Nonwhite races consisted of African American (n
= 3), Asian (n = 1), and other (n = 1). All patients were receiving the mycophenolate mofetil
prodrug of MPA, with the exception of one patient (prescribed mycophenolate sodium), who
was included in the analyses, as the pharmacokinetics were similar. The average MPA daily
dose was 1489 ± 596 mg with dosing divided twice daily in all but one patient, who was dosed
once daily. The distribution of doses was 250 mg (n = 1), 500 mg (n = 9), 750 mg (n = 4), 1000
mg (n = 8), and 1500 mg (n = 1). Clinical laboratory results were serum creatinine 1.3 ± 0.6
mg/dL (range 0.7–3.4), UP:Cr 0.42 ± 0.50 (range 0.04–1.87), CrCl 84.4 ± 40.1 mL/min (range
18.3–182.2), and serum albumin 4.4 ± 0.40 g/dL (range 3.6–5.2). Thirty percent (n = 7) of the
patients were receiving concomitant glucocorticoids and 13% (n = 3) were receiving
cyclosporine.
MPA Pharmacokinetics
A concentration versus time profile for one patient at steady-state MPA and MPAG
concentrations over 12 hours is presented in Figure 1. The mean pharmacokinetic parameters
for patients with ANCA vasculitis are provided in Table 1. The scaled Cl/F of 288 ± 154 mL/
min suggests that MPA is a moderate extraction ratio drug whose metabolism could be
impacted by changes in unbound fraction. The mean percentage of unbound MPA was 1.0 ±
0.6%, with all patients having unbound fractions of 2.4% or less, similar to the expected
unbound fraction.11,21 The MPA AUC0-12 was outside the 30- to 60-mg•h/L range that was
recommended in kidney transplant patients within the first 6-month period posttransplant,22
with 22% (n = 5) of patients above and 30% (n = 7) below this range. Examination of the
AUC6-12 to the AUC0-12 suggested that recycling accounted for 34 ± 10% of the AUC, which
is within the previously published range.21,22
The Ctr at 12 hours exceeded the range of 1.0–3.5 mg/L that is recommended in transplant
patients,22 with 22% (n = 5) above this target. The tmax varied from 0.5 to 5 hours, severely
limiting applicability of shortened plasma collections for AUC determination.
The MPA Clr represented 2% of the Cl/F, which is consistent with previous reports.21 As
suggested previously, the clearance of MPA is primarily the result of systemic metabolism to
MPAG.11 The Clr of MPA was 5.77 ± 5.80 mL/min, which was 9% of the CrCl in our patients.
MPAG Pharmacokinetics
The MPAG pharmacokinetic results are reported in Table 1. A calculated AUC0-12 ratio of
MPAG to MPA resulted in a metabolic ratio of 8.67 ± 5.57, less than previously reported in
renal transplant recipients.23
The renal clearance of MPAG was 33.7 ± 34.9 mL/min, representing 40% of the CrCl. The
kidneys contributed to the elimination of 97% of the MPA dose, primarily through excretion
of MPAG. The amount of MPAG in the urine over the 0- to 12-hour interval (513 ± 285 mg)
was more than the amount in the 12- to 24-hour interval (378 ± 257 mg; p = 0.017). The Clr
was also greater in the 0- to 12-hour (33.7 ± 34.9 mL/min) versus 12- to 24-hour dosing interval
(28.4 ± 36.9 mL/min; p = 0.0043).
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Our data showed that 1.0% and 13% of MPA and MPAG, respectively, were unbound in the
plasma. Since the unbound MPAG was less than that reported previously,21 we performed
studies with MPA and/or MPAG spiked heparinized plasma.17 The plasma that was spiked
separately demonstrated similar unbound percentages to those found in our ANCA patient data;
the combination of drug and metabolite resulted in an increase in unbound percentage of MPA
and MPAG. This may be suggestive of competitive binding to albumin, as has been reported
previously.24
Since the normal percentage of unbound MPA is 2%, if one aims for a total MPA Ctr of 1.0–
3.5 mg/L, then an unbound target would be 0.02–0.07 mg/L.21 Likewise, if suggested total
AUC goals are 30–60 mg•h/L, then unbound AUC goals would be 0.6–1.2 mg•h/L. Mean
unbound Ctr levels were 0.04 ± 0.06 mg/L (consistent at both the 12- and 24-h time points),
with 5 patients exceeding the range and 13 patients below the range; this resulted in only 22%
of all patients falling within the targeted kidney transplant range. With regard to unbound AUC,
the mean exposure was greater than the upper range of 1.2 mg•h/L in only 1 patient, but was
less than the targeted range in 15 patients.
Regression Results
The multiple regression model for MPA Cl/F revealed that race and weight contributed: ranked
Cl/F = −11.766 + 0.2035(wt) + 4.9578(race); R2 41.8%; p = 0.005. The AUC6-12 showed the
following relationship: Ln MPA AUC6-12 = 3.706 − 0.0094(CrCl); R2 36.86%; p = 0.0021. In
analysis of MPA Clr, the AUC6-12 was the only significant contributing variable: ranked MPA
Clr = 30.2674 − 6.2733(ln AUC6-12); R2 33.2%; p = 0.004. Regression assessment of the
predictors for unbound MPA clearance indicated that CrCl and age were important: Ranked
Clunb = 16.055 + 0.0601(CrCl) − 0.1994(age); R2 52.3%; p = 0.0013. MPAG Clr analysis
showed that race and prednisone dose contributed. Ln MPAG Clr = 2.6645 + 1.1799(race) −
0.3041(ranked prednisone dose); R2 88.0%; p = 0.014.
Comparison Between Groups Based on Clinical Laboratories
The differences in pharmacokinetics by clinical grouping of UP:Cr (<500 vs ≥500) and CrCl
(<60 mL/min vs ≥60 mL/min) were assessed (Table 2). There was a considerable distribution
of CrCl across the population (low 18.3 mL/min, high 182 mL/min). Since MPAG is eliminated
via the renal route, reductions in renal elimination would be predicted to have more direct
effects on MPAG, with secondary effects on MPA due to potential enhanced MPA AUC6-12,
reflective of enterohepatic recycling (Table 2).
The MPA Ctr values were 3-fold higher in patients with reduced CrCl compared with those
who had higher CrCl (6.88 ± 6.8 vs 2.72 ± 1.81, respectively; p = 0.030). The AUC6-12
demonstrated 2 to 3-fold higher values in low versus high CrCl grouping (35.9 ± 27.0 vs 16.7
± 8.8 mg•h/L, respectively; p = 0.015). The MPA AUC0-12 was 2-fold greater in the low versus
high CrCl grouping (95.0 ± 66.9 vs 52.5 ± 22.8 mL/min, respectively; p = 0.023). The MPA
AUC0-12 unbound values were significantly higher in the low CrCl group (1.29 ± 0.608 vs
0.592 ± 0.562 mg•h/L; p = 0.032), suggesting the presence of more pharmacologically active
drug. The MPA Clunb was 3-fold reduced in the low CrCl group, with a trend toward statistical
significance, which may be suggestive of reduced metabolism and/or CrCl. While the Clr
MPAG was not significantly different between groups, the MPAG AUC0-12 was enhanced 2-
fold in the low CrCl patient group (959 ± 664 vs 404 ± 336 mg•h/L; p = 0.014).
UP:Cr was selected as a clinical variable secondary to the high plasma protein binding
characteristics of MPA and MPAG. To enable at least 5 observations per group, a cut-point of
500 mg/day was selected. None of the pharmacokinetic parameters was statistically significant
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between the high and low UP:Cr grouping. Only 4 patients had UP:Cr greater than 1.0 g/day,
preventing a comparison that may be more likely to be clinically relevant.
Discussion
While descriptions of the pharmacokinetics of MPA in patients who have undergone kidney
transplant are abundant, there is a paucity of data on the pharmacokinetics in autoimmune
diseases that affect the kidney. Our study was conducted to comprehensively evaluate the
pharmacokinetics of MPA and MPAG after chronic therapy in patients with ANCA-associated
vasculitis. Additionally, we wanted to understand the relevance of clinical and demographic
variables in predicting pharmacokinetic parameters. CrCl was positively predictive for MPA
Clunb and negatively predictive for MPA AUC6-12. Race was found to positively predict both
MPA Cl/F and MPAG Clr, whereby nonwhite patients had higher clearance values, suggesting
an influence on both metabolism and Clr. Prednisone dosage was negatively associated with
MPAG Clr, suggesting an influence on active renal secretion. Unfortunately, the influences of
UP:Cr and serum albumin on pharmacokinetic variables were not able to be fully assessed
secondary to limited distribution of UP:Cr and relatively conserved values of serum albumin.
A study of MPA use in patients with lupus nephritis showed that at a UP:Cr of 1 g/day or more,
Ctr and AUC0-12 were significantly reduced and Cl/F was significantly increased.17 We
previously reported higher MPA Clunb and MPAG Clr levels in patients with lupus nephritis
patients with serum albumin levels less than 4 g/dL versus those with levels greater than or
equal to 4 g/dL.17
CrCl significantly affected the pharmacokinetics of MPA and MPAG in ANCA-associated
vasculitis. Although MPA itself is not highly eliminated by the kidneys, exposure was markedly
enhanced in the low CrCl grouping, with dosing interval (AUC0-12), enterohepatic recycling
(AUC6-12), and unbound (AUC0-12unb) exposures being significantly greater. Since MPAG is
primarily eliminated by renal excretion, reductions in CrCl may predispose patients to higher
concentrations of MPAG, which, through recycling, can increase systemic exposure to MPA.
These results suggest that patients with diminished kidney function can reach targeted MPA
exposure ranges with lower dosages, thus minimizing adverse events. Lower unbound MPA
(eg, AUC) would not be predicted to be increased through a purely restrictive clearance
mechanism, and our patients were not hypoalbuminemic; hence, our data may suggest the
influence of additional factors affecting plasma concentrations in patients with glomerular
kidney diseases. Assessment of MPA Ctr values showed a consistent 2- to 3-fold higher value
in patients with CrCl less than 60 mL/min compared with those with CrCl greater than 60 mL/
min. When we performed a post hoc analysis of variance to evaluate the differences in
pharmacokinetics based on CrCl groupings, we found that significant differences in Ctr,
recycling AUC, unbound AUC, and unbound clearance were all demonstrated between the
patients with chronic kidney disease stage 3/4 versus stage 1 group. Only unbound clearance
was found to also be significant between the stage 3/4 versus stage 2 group.
The pharmacokinetics of MPA in patients with ANCA vasculitis are comparable with
pharmacokinetics in renal transplant patients, with the exception of Cl/F, which is about 2-fold
greater in patients with vasculitis. Reasons for enhanced Cl/F can include increased systemic
metabolism secondary to upregulated glucuronidation, increased MPA unbound fraction, or
enhanced renal excretion. Regarding enhanced glucuronidation, patients receiving concurrent
steroids (enzyme inducers) had similar Cl/F estimates as patients who were not receiving
steroids (data not shown). We are currently evaluating the contribution of enhanced catalysis
polymorphisms in the uridine diphosphate glucuronosyltransferases (UGTs) as factors altering
MPA clearance. The metabolic ratio, a reflection of metabolite to parent AUC, was 8.67 ± 5.57
in our study, considerably less than the 25.6 ± 8.7 that was previously reported in kidney
transplant recipients.23 The unbound fraction was relatively normal (∼1%) in our patients, as
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they had essentially normal serum albumin concentrations (3.6–5.2 g/dL). Enhanced renal
clearance can result from increased CrCl, loss of highly protein-bound drugs with urinary
protein, or enhanced secretory transport mechanisms. Our patients with ANCA vasculitis had
a mean CrCl of 84 mL/min, with a range between 18 and 182 mL/min. Although renal
elimination of MPA is limited, enhanced CrCl could result in increased clearance secondary
to renal clearance of the polar metabolite MPAG. Enhanced renal clearance secondary to loss
of the highly protein bound MPA with the urinary protein could also account for an increase
in Cl/F. However, when we evaluated Clr between patients with UP:Cr less than 500 mg/day
and those with UP:Cr greater than or equal to 500 mg/day, the results were similar. The
magnitude of differences in Clr between UP:Cr groups may have been underappreciated, based
on our selected cut-point. MPAG is a substrate for MRP2, an efflux transporter found on the
luminal surface of the proximal tubule. Theoretically, single nucleotide polymorphisms (SNPs)
in this transport gene can result in enhanced activity and could increase the renal excretion of
MPAG, limiting the effect of recycling.
Renal transplant recipients, similar to our ANCA vasculitis patients, generally have reductions
in CrCl. A previous study used a multivariate analysis and demonstrated that 24% of the MPA
Cl/F could be explained by proteinuria (yes/no), glomerular filtration rate, and diabetes
mellitus.25 Unfortunately, the range of proteinuria required to designate a yes versus no
categorization was not reported. Our regression data showed that CrCl was predictive for both
Clunb and AUC6-12. Previous data on lupus nephritis from our laboratory showed that 51% of
MPA Cl/F could be explained by CrCl and serum albumin, 2 readily measured clinical
laboratory measures.17 The contribution of race to MPA Cl/F in our vasculitis patients requires
assessment of genotype as a confounding variable, as genomic effects have been shown to
influence the pharmacokinetics of MPA.19,20,26 CrCl would generally be predicted to
contribute little to MPA Cl/F, secondary to the low percentage of MPA (1–3%) that is normally
excreted by the kidneys. Hence, nonrenal clearance, through metabolism of MPA to MPAG,
would comprise the largest bulk of the Cl/F for MPA. Our regression analyses demonstrated
that AUC6-12 was the only significant predictor of MPA Clr, demonstrating an influence of
MPA plasma concentration on Clr. The regression models are important, as they provide
insights into the mechanisms that may underlie the alterations in pharmacokinetics seen in
disease states such as ANCA-associated vasculitis. This is particularly important, since there
is a paucity of published research on medication off-label disease groups, whereby there can
be extensive variations in medication handling versus in the diseases for which the drugs were
FDA approved.
Unlike our ANCA vasculitis patients, our previous report on MPA pharmacokinetics in patients
with lupus nephritis showed higher UP:Cr and lower serum albumin and CrCl.17 The key
differences in pharmacokinetics of MPA and MPAG between these studies included enhanced
MPA MRT, MPA Clr, metabolic ratio (MPAGAUC/MPAAUC), unbound MPAG %, and MPA
Cl/Funb; reduced MPA AUC0-12, MPA AUC6-12, MPAG Clr, MPA Ctrunb, and MPA
AUCunb; and normal unbound MPA % in the ANCA vasculitis versus lupus nephritis
population. These data generally demonstrate lesser MPA exposure in patients with ANCA-
associated vasculitis as opposed to those with lupus nephritis. While lower MPA dosages in
the ANCA vasculitis populations could reflect reduced exposure, our data were dose-
normalized to eliminate the dose effect. The effects of SNPs in UGT enzymes requires
assessment in these autoimmune diseases, especially since environmental exposure is thought
to play a role in their etiology and since the UGT enzymes play a role in the body's natural
defense against environmental toxins. Additionally, the role of inflammation in MPA
pharmacokinetics in autoimmune diseases requires evaluation as a potential disease component
that may modify drug metabolism and transport.
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While we report the contribution of CrCl to MPA clearance and exposure in a model of ANCA
vasculitis, there are some limitations to our research. As noted previously, our patients had
preserved serum albumin concentrations, preventing full assessment of the contribution of
reductions in serum albumin on clearance. Similarly, since only 4 patients in our dataset had
UP:Cr of approximately 1 g/day and none had nephrotic-range proteinuria (UP:Cr >3.5 g/day),
the full contribution of UP:Cr to clearance may actually be underrecognized. Future analyses
of our data include assessment of the contribution of genotype for drug-metabolizing enzymes
and transporters on clearance and outcomes, as well as the analysis of the contribution of Ctr
and AUC to patient outcomes. Our studies on autoimmune-related kidney diseases are
important, as they provide a framework to understand the contributions of disease-related and
-unrelated factors to MPA exposure. A goal of our future work is to better define appropriate
MPA concentration or exposure targets for patients with ANCA-associated vasculitis.
Approaches to comprehensively evaluate the influence of clinical and demographic factors on
MPA pharmacokinetics are needed to begin to identify variables that could be used to
individualize treatment strategies for patients with ANCA-associated vasculitis.
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metabolite (MPAG) after chronic dosing (every 12 hours) in one patient.
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Table 1
Pharmacokinetic Parameters in Patients with ANCA-Associated Vasculitisa
MPA
 tmax (h) 1.46 ± 1.24
 Cmax (mg/L)
b 21.5 ± 20.3
 Ctr12 (mg/L)
b 3.99 ± 4.32
 lambda (h−1) 0.07 ± 0.04
 MRT (h) 27.2 ± 36.2
 AUCMPA0-12 (mg•h/L)
b 65.4 ± 44.4
 AUCMPA6-12 (mg•h/L)
b 22.6 ± 18.3
 Cl/F (mL/min)c 288 ± 154
 Clr0-12 (mL/min)
c 5.77 ± 5.80
 Ae0-12 (mg) 13.6 ± 12.2
 % unbound 1.02 ± 0.66
MPAG
 tmax (h) 2.51 ± 1.44
 Cmax (mg/L)
b 74.3 ± 58.9
 Ctr12 (mg/L)
b 35.1 ± 32.3
 lambda (h−1) 0.07 ± 0.04
 AUCMPAG0-12 (mg•h/L)
b 573 ± 515
 MPAG:MPA ratio 8.67 ± 5.57
 Clr0-12 (mL/min)
c 33.7 ± 34.9
 Ae0-12 (mg) 513 ± 285
 % unbound 12.9 ± 7.0
Unbound MPA
 Cmax (mg/L)
b 0.22 ± 0.24
 Ctr12 (mg/L)
b 0.04 ± 0.06
 AUCMPA0-12 (mg•h/L)
b 0.76 ± 0.64
 Cl/F (L/min)c 37.0 ± 29.6
Ae = amount excreted in the urine; ANCA = antineutrophil cytoplasmic antibody; AUC = area under the plasma concentration–time curve; Cmax =
maximum plasma concentration; Cl/F = oral clearance; Clr = renal clearance; Ctr12 = trough plasma concentration at 12 hours; MPA = mycophenolic




Normalized to a 1000-mg dose.
c
Scaled to a body size of 70 kg, using 0.75 power.
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Table 2
Clinical Grouping of Patients and Pharmacokineticsa
Pharmacokinetic Parameter Status p Value
CrCl <60 mL/min ≥60 mL/min
Pts., n 7 16
MPA
 % unbound 0.9 ± 0.7 1.1 ± 0.7 0.598
 Ctr12 (mg/L)
b 6.88 ± 6.79 2.72 ± 1.81 0.030
 AUC0-12 (mg•h/L)
b 95.0 ± 66.9 52.5 ± 22.8 0.023
 AUC6-12 (mg•h/L)
b 35.9 ± 27.0 16.7 ± 8.8 0.015
 Cl/F (mL/min)c 210 ± 86.7 323 ± 67 0.109
 Clr0-12 (mL/min)
c 3.36 ± 3.07 6.77 ± 6.48 0.340
 Clunb (mL/min)
c 15,928 ± 637643,539 ± 31,045 0.067
 AUC0-12unb (mL/min)
b 1.29 ± 0.608 0.592 ± 0.562 0.032
 MRT (h) 36.9 ± 35.9 23.4 ± 36.8 0.452
MPAG
 AUC0-12 (mg•h/L)
b 959 ± 664 404 ± 336 0.014
 Clr0-12 (mL/min)
c 21.8 ± 20.2 38.9 ± 39.1 0.249
MPAG AUC0-12/MPA AUC0-12 10.7 ± 6.19 7.77 ± 5.24 0.278
UP:Cr <500 mg/day ≥500 mg/day
Pts., n 15 6
MPA
 % unbound 0.99 ± 0.65 1.21 ± 0.78 0.516
 Ctr12 (mg/L)
b 3.07 ± 1.79 6.56 ± 7.87 0.381
 AUC0-12 (mg•h/L)
b 55.8 ± 22.3 84.5 ± 80.6 0.791
 AUC6-12 (mg•h/L)
b 18.9 ± 9.18 32.2 ± 32.6 0.153
 Cl/F (mL/min)c 300 ± 163 285 ± 165 0.970
 Clr0-12 (mL/min)
c 5.47 ± 6.08 7.31 ± 6.23 0.569
 Clunb (L/min)
c 43.5 ± 33.5 19.7 ± 12.5 0.145
 AUC0-12unb (mg•h/L)
b 0.82 ± 0.74 1.25 ± 0.82 0.186
 MRT (h) 24.2 ± 37.8 43.4 ± 36.8 0.186
MPAG
 AUC0-12 (mg•h/L)
b 467 ± 366 860 ± 798 0.733
 Clr0-12 (mL/min)
c 28.1 ± 19.5 45.9 ± 62.0 0.791
Metabolic ratio 8.46 ± 5.57 9.95 ± 6.48 0.340
AUC = area under the plasma concentration–time curve; Cl/F = oral clearance; Clr = renal clearance; CrCl = creatinine clearance; Ctr12 = trough plasma
concentration at 12 hours; MPA = mycophenolic acid; MPAG = mycophenolic acid glucuronide; MRT = mean residence time; unb = unbound; UP:Cr =
urinary protein to creatinine excretion ratio.
a
Mean ± SD, unless otherwise indicated.
b
Normalized to a 1000-mg dose.
c
Scaled to a body size of 70 kg, using 0.75 power.
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